Stock CPHL CITI PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Citi Pharma Limited

Equities

CPHL

PK0126201018

Pharmaceuticals

End-of-day quote Pakistan S.E.
Other stock markets
 06:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
31.16 PKR -1.24% Intraday chart for Citi Pharma Limited -1.36% +31.26%
2023 Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
2023 33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2023. CI

Valuation

Fiscal Period: June 2022 2023
Capitalization 1 7,457 4,875
Enterprise Value (EV) 1 6,403 5,138
P/E ratio 11.7 x 7.41 x
Yield - 11.7%
Capitalization / Revenue 0.76 x 0.39 x
EV / Revenue 0.65 x 0.41 x
EV / EBITDA 6.07 x 4.09 x
EV / FCF -4,332,307 x -3,905,471 x
FCF Yield -0% -0%
Price to Book 1.59 x 0.91 x
Nbr of stocks (in thousands) 228,461 228,461
Reference price 2 32.64 21.34
Announcement Date 10/11/22 10/6/23
1PKR in Million2PKR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 2,003 2,607 3,528 5,795 9,780 12,397
EBITDA 1 183.7 181.8 303.8 636.7 1,055 1,255
EBIT 1 135.5 136.4 258.5 571 982.5 1,167
Operating Margin 6.76% 5.23% 7.33% 9.85% 10.05% 9.42%
Earnings before Tax (EBT) 1 116.9 114.3 206.9 499.7 1,033 957.3
Net income 1 116.9 81.68 145.6 351.8 635.9 658
Net margin 5.83% 3.13% 4.13% 6.07% 6.5% 5.31%
EPS 2 1.180 0.8250 1.471 2.369 2.800 2.880
Free Cash Flow - 239.1 -34.68 428.5 -1,478 -1,315
FCF margin - 9.17% -0.98% 7.39% -15.11% -10.61%
FCF Conversion (EBITDA) - 131.48% - 67.3% - -
FCF Conversion (Net income) - 292.71% - 121.81% - -
Dividend per Share - - - 1.364 - 2.500
Announcement Date 10/7/19 10/7/19 10/5/20 10/7/21 10/11/22 10/6/23
1PKR in Million2PKR
Estimates

Balance Sheet Analysis

Fiscal Period: June 2021 2022 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - 14% 17% 20%
ROA (Net income/ Total Assets) - 8.72% - -
Assets - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - 586 - -
Capex / Sales - 5.99% - -
Announcement Date 9/30/21 10/11/22 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
31.16
Average target price
-
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CITI PHARMA LIMITED Stock Citi Pharma Limited
+31.26% 25.92M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.37% 588B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.60% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.83% 326B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.83% 239B
NOVARTIS AG Stock Novartis AG
+9.93% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.95% 200B
AMGEN INC. Stock Amgen Inc.
+10.77% 167B
PFIZER, INC. Stock Pfizer, Inc.
+0.10% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CPHL Stock
  4. Financials Citi Pharma Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW